Inhibrx Biosciences (INBX) Research & Development (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Research & Development data on file, last reported at $25.3 million in Q4 2025.

• Research & Development for Q4 2025 came in at $25.3 million, down 24.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $113.0 million (down 44.52% YoY), and the FY2025 annual result was $113.0 million, down 44.52% from the prior year.
• Research & Development fell to $25.3 million in Q4 2025 per INBX's latest filing, from $28.5 million in the prior quarter.
• Over five years, Research & Development peaked at $82.1 million in Q4 2023 and troughed at $22.3 million in Q2 2025.
• A 3-year average of $42.8 million and a median of $36.9 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development surged 98.3% in 2024, then sank 67.08% in 2025.
• A 3-year view of Research & Development shows it stood at $82.1 million in 2023, then slumped by 59.35% to $33.4 million in 2024, then retreated by 24.03% to $25.3 million in 2025.
• Business Quant data shows INBX's Research & Development at $25.3 million in Q4 2025, $28.5 million in Q3 2025, and $22.3 million in Q2 2025.